Growth. Value. Beautiful fundamentals. Strong growth prospects. Oversold and underappreciated.

6.2

Pharm stock in China, perscription and natural drugs that work.

Buy -- Price 3.54 on March 10
by Roth Capital Partners

Shares now trade for four times [fiscal] "09 [earnings-per-share] estimates versus peers' 12 times; using the peer multiple [would value] AOB at 10 a share. We are confident AOB will benefit from China's health-care initiative ($124 billion/next three years). The shares [look] attractive ... given the modest valuation and growth potential of the business. Market cap: $277 million.

Small, well-managed, poised to take on major market

Over sold.
7.33

good chinese pharma co

-36.36%

American Oriental Bioengineering recently announced that its Board of Directors has authorized a share repurchase program for the repurchase of up to $75 million of the Company's outstanding common stock.

The stock trades for 10x cash flow.

Took a chance on a "china Stock" and it has been paying off so far

Still have a few shares long, but Chinese plays are so frustrating. Lesson learned.

Another bio-pharma. All "good news" but no good price action. I stay away from pharma because I don't understand it. It is not transparent, too much government involvement.

my china spec play, just can't get rid of it

company seems clouded in misinformation

Big Loss here

.71